Signal's new Windows update prevents the system from capturing screenshots of chats
Signal said today that it is updating its Windows app to prevent the system from capturing screenshots, thereby protecting the content that is on display.
The company said that this new 'screen security' setting is enabled by default on Windows 11. Signal said that this new feature is designed to protect users' privacy from Microsoft's Recall feature, which was announced last year. Recall captures screenshots of the system continuously to remember all of your activities, so you can scroll back in time to remember what you were looking at.
While the company paused the rollout of the feature last year after backlash, Microsoft started testing it again in April through the Windows Preview Channel. Microsoft has made the feature opt-in and has also added a way to pause it anytime. Signal said that despite these changes, the feature still captures content that may be sensitive.
Signal said that when you are trying to take a screenshot with the new screen security setting enabled, you will just get a blank screen.
The company also warned that when the setting is enabled, some functions, such as screen readers, might not work as intended. You can turn off the setting through Signal Settings > Privacy > Screen security.
The app will show you a warning when you are trying to disable this option, and you will have to click on Confirm to complete the action. This is to prevent you from accidentally turning the feature off while trying to adjust other settings.
'We hope that the AI teams building systems like Recall will think through these implications more carefully in the future. Apps like Signal shouldn't have to implement a 'one weird trick' in order to maintain the privacy and integrity of their services without proper developer tools,' Signal said in a blog post.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
13 minutes ago
- Yahoo
If You Can Only Buy 1 Cathie Wood Stock in 2025, It Should Be This
Cathie Wood, founder, CEO and chief investment officer of Ark Invest, continues to make headlines for her high-conviction approach to disruptive innovation. Her flagship fund, the Ark Innovation ETF (ARKK), has posted a 52.9% return in the past 52 weeks, reflecting investor confidence. Known for identifying transformational themes early, Wood maintains focused exposure to industries like genomics, autonomous technology, and blockchain. Within this context, Natera (NTRA) has drawn sharp relevance. The company leads in cell-free DNA testing and precision medicine, aligning directly with Ark's long-term thesis. CoreWeave Just Revealed the Largest-Ever Nvidia Blackwell GPU Cluster. Should You Buy CRWV Stock? AMD Is Gunning for Nvidia's AI Chip Throne. Should You Buy AMD Stock Now? The Saturday Spread: Statistical Signals Flash Green for CMG, TMUS and VALE Tired of missing midday reversals? The FREE Barchart Brief newsletter keeps you in the know. Sign up now! For investors seeking a stock that fits the Ark playbook, Natera may represent one of the most fundamentally aligned additions under Wood's current investment lens. Based in Austin, Texas, stands Natera (NTRA), a pioneer in the field of cell-free DNA and genetic testing. The $23.3 billion biotech firm's arsenal includes powerful offerings like Panorama for prenatal screening, Signatera for real-time cancer surveillance, and Prospera, which sharpens the lens on transplant rejection. Over the last three months, the stock has climbed 16.9%, leaving the broader S&P 500 Index's ($SPX) 5.4% gain behind. On May 8, Natera opened the books on its first-quarter, and the results exceeded Wall Street expectations. Investors responded swiftly, with the stock inching up 1.5% the same day. Natera posted $501.8 million in total revenues, a 36.5% year-over-year increase that soared past Wall Street's $443.3 million forecast. Behind those numbers were powerhouse operations. The company processed 855,100 tests during the quarter, up 16.2% year over year. Women's health volumes climbed meaningfully over the fourth quarter, but it was Signatera that stole the spotlight. The personalized, tumor-informed molecular residual disease test reached new heights, recording its highest volume quarter ever. Clinical volumes for Signatera grew 52% year over year, with a sequential gain of roughly 16,005 units over Q4, marking the most significant quarter-on-quarter growth to date. Gross margins landed at 63.1%, reflecting solid cost discipline. Moreover, Natera's net loss narrowed 1% from the year-ago period to $66.9 million. Also, the company managed to trim its loss per share by 10.7% to $0.50, outperforming analysts' projections of a $0.59 loss per share. As for liquidity, the balance sheet remained in good shape. Cash, cash equivalents and restricted cash climbed to $973.8 million, up from $945.6 million on Dec 31, 2024. CEO Steve Chapman has made no secret of the firm's long-term vision. He believes Signatera could ultimately generate over $5 billion in annual revenue, and he emphasized that they are still playing in the shallow end of a much deeper market pool. In a move that reinforced this optimism, Natera has raised its full-year revenue guidance to between $1.94 billion and $2.02 billion. That is a $70 million boost from the midpoint of its earlier outlook, pointing to a 26% year-over-year growth. On the other hand, analysts expect the Q2 2025 loss per share to widen 100% year over year to $0.60. For FY25, the loss per share is projected to increase 37% to $2.10, but FY26 could bring relief, with a forecast 64.8% narrowing to $0.74, hinting that profitability may finally be within reach. Analysts seem to be singing in harmony when it comes to NTRA, marking it with a firm 'Strong Buy' rating. Out of 19 analysts following the stock, 16 have given it an enthusiastic 'Strong Buy' rating, and the remaining three have placed their bets on a 'Moderate Buy.' The average price target of $200.42 represents potential upside of 17.6%. Meanwhile, the Street-High target of $251 hints at a 48% climb from current levels. Such projections do not come lightly and often reflect deep-rooted confidence in future earnings momentum and strategic execution. On the date of publication, Aanchal Sugandh did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
22 minutes ago
- Yahoo
Company makes game-changing breakthrough that could solve common issue with plant-based food — here's what you need to know
Let's be honest: Plant-based protein doesn't always taste great. Even if you love the idea of eating less meat for your health and the planet, the weird aftertaste of some plant-based meats can be hard to ignore. But that might be about to change. According to FoodNavigator USA, the flavor company T. Hasegawa USA has developed a high-tech, natural flavor that tackles the unpleasant "off" notes of plant proteins such as pea and soy. The whole technology (and science) behind it is pretty impressive. When meat sizzles in a pan or bread gets crispy in the toaster, the Maillard reaction creates craveable aromas and flavors. But plant proteins such as soy and pea don't react the same way during cooking, which can leave them tasting bland or, worse, beany and bitter. If companies want people to go for meat alternatives, there's a need to focus on options that taste good and have pleasant textures. As Mark Webster, vice president of sales and marketing at T. Hasegawa, said, "That is where the headwind is." The T. Hasegawa team tackled this problem by developing a natural flavor technology called Plantreact that increases Maillard reactions — the chemical processes that give so-called browned foods their flavors. This innovation doesn't stop with fake meats. The same flavor solution can also recreate creamy, dairy-like notes in alternative milks and other nondairy products. That's huge for people who love the idea of oat or almond milk but miss the full-bodied taste of cow's milk. Plantreact has been in the works for a while, but it's now ready to hit the market. T. Hasegawa is already working with food brands to roll it out in products. Better flavor means plant-based foods are more enjoyable, which makes it easier for more people to cut back on animal products and reduce pollution, conserve water, and shrink their carbon footprints. This tech is already being explored by plant-based brands looking to improve their products, and it may soon appear in alternative meat and dairy products at your local grocery store. Combined with the work of companies such as Meati and Perfect Day, this kind of innovation helps build a future in which eating more sustainably doesn't mean compromising on taste. Why do you eat plant-based foods? The health benefits It's cheaper It's good for the planet I prefer the taste Click your choice to see results and speak your mind. Join our free newsletter for easy tips to save more and waste less, and don't miss this cool list of easy ways to help yourself while helping the planet.
CNBC
22 minutes ago
- CNBC
How a 'brag doc' can help you ace interviews and land a job, says recruiter: ‘No one's reading cover letters'
One of the best pieces of advice Maddie Machado received from a former boss at Microsoft was to keep track of all her career wins. Machado would log "anytime I did a good job, anytime I made someone's life easier, anytime I got kudos" first in a Microsoft document, then a running email draft and now in a slide presentation. She calls it a "brag doc" and says she's used it in every interview for the last 10 years. Machado, 35, is a reverse recruiter and founder of SkillScript, a resume platform, in Tampa, Fla. The concept of documenting your career wins isn't new, but her method categorizes four specific aspects of your professional success: Machado says having a brag doc on hand can help you network and could make a bigger impact than a traditional resume or cover letter. "No one's reading cover letters," Machado says. "Even when I was a recruiter for so many years, I can count on maybe one hand how many times I actually read a cover letter." A brag doc, meanwhile, is "a time for you to toot your own horn," Machado says. "It's hard to see on your resume the amount of impact and the things that you actually owned and are actually proud of." It also shows off the most important aspects of a candidate a hiring manager wants to know, Machado says, based on her time working with hiring managers at companies like Meta and LinkedIn. Hiring managers will generally already know what you do day-to-day in your role, Machado says, but are looking for what you'll bring to a new company and things that will make them think, "Wow, look at what she did there. Imagine what she could do here," she says. "And that's what your brag doc is doing." A brag doc is a useful resource to attach to your application, to follow up with a hiring manager on LinkedIn after you've applied for a role, or even to cold-message someone to network, Machado says. It won't necessarily get you the job right away, but it could get you in the hiring pipeline that much faster. Then, use it to prepare for interviews and negotiate a strong offer, Machado says. "It's nice to be able to remind yourself what you've accomplished so far, whether it's big or small, and also be able to share with other people," she says.
